ES2702246T3 - Formulaciones de agente de unión IgG4 estables - Google Patents

Formulaciones de agente de unión IgG4 estables Download PDF

Info

Publication number
ES2702246T3
ES2702246T3 ES13714505T ES13714505T ES2702246T3 ES 2702246 T3 ES2702246 T3 ES 2702246T3 ES 13714505 T ES13714505 T ES 13714505T ES 13714505 T ES13714505 T ES 13714505T ES 2702246 T3 ES2702246 T3 ES 2702246T3
Authority
ES
Spain
Prior art keywords
antibody
formulation
cxcr5
light
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13714505T
Other languages
English (en)
Spanish (es)
Inventor
Dirk Usener
Ahmed Youssef
Annika Hagendorf
Martina Kirsch
Sabrina Ruggeberg
Julia Schnieders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/US2013/033881 external-priority patent/WO2013148686A2/en
Application granted granted Critical
Publication of ES2702246T3 publication Critical patent/ES2702246T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES13714505T 2012-03-26 2013-03-26 Formulaciones de agente de unión IgG4 estables Active ES2702246T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615539P 2012-03-26 2012-03-26
FR1351013 2013-02-06
PCT/US2013/033881 WO2013148686A2 (en) 2012-03-26 2013-03-26 Stable igg4 binding agent formulations

Publications (1)

Publication Number Publication Date
ES2702246T3 true ES2702246T3 (es) 2019-02-28

Family

ID=54834982

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13714505T Active ES2702246T3 (es) 2012-03-26 2013-03-26 Formulaciones de agente de unión IgG4 estables

Country Status (4)

Country Link
JP (1) JP6820823B2 (ja)
ES (1) ES2702246T3 (ja)
HK (1) HK1204990A1 (ja)
PT (1) PT2830658T (ja)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP5290152B2 (ja) * 2006-04-21 2013-09-18 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
CA2661782C (en) * 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
US20110130544A1 (en) * 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
UA117446C2 (uk) * 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20130086144A (ko) * 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물

Also Published As

Publication number Publication date
JP2018048174A (ja) 2018-03-29
HK1204990A1 (en) 2015-12-11
PT2830658T (pt) 2018-12-28
JP6820823B2 (ja) 2021-01-27

Similar Documents

Publication Publication Date Title
US10525130B2 (en) Stable IGG4 based binding agent formulations
US10689451B2 (en) Anti-BAFFR antibody therapeutic formulations
ES2827180T3 (es) Formulaciones de anticuerpos estables
CN104736175B (zh) 抗催乳素受体抗体制剂
ES2818229T3 (es) Formulación anti-IFNAR1 estable
BR112014023952B1 (pt) Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios
KR102624564B1 (ko) 항-ctla4 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-ctla4 항체의 안정한 제제 및 그의 사용 방법
ES2925992T3 (es) Formulaciones estables de polipéptidos
ES2732243T3 (es) Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20110256135A1 (en) Anti-nerve growth factor (ngf) antibody compositions
ES2860480T3 (es) Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
CN104768578A (zh) 稳定的低粘度抗体配制品
KR102594028B1 (ko) 항-pd-1 항체 조성물
US20220111048A1 (en) Antibody formulations
US20210087267A1 (en) Liquid formulations of anti-cd200 antibodies
TW202045136A (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
ES2702246T3 (es) Formulaciones de agente de unión IgG4 estables
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
CA3235879A1 (en) Pharmaceutical formulation comprising anti-ox40 monoclonal antibody
KR20240038005A (ko) B7-h3 항체의 약학적 조성물 및 그것의 용도